Role of Extracellular Vesicles in Cancer Progression

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1055

Special Issue Editor


E-Mail Website
Guest Editor
Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
Interests: exosomes; extracellular vesicles; metastasis; tumour immunity; liquid biopsy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Extracellular vesicles (EVs) are a heterogenous group of membrane-bound vesicles secreted by cells across all living kingdoms. They take part in cell-to-cell communication, and the mechanisms, messages and efficiency of this exchange system are currently under extensive investigation as they are involved in multiple physiological, as well as pathological processes.

Remarkably, EV secretion appears to be augmented in tumor cells and has a relevant role in cancer progression, offering a highly effective way to modulate the tumor microenvironment, contributing to the formation of pre-metastatic and metastatic niches, and participating in the tumor–immune landscape cross-talk.

This Special Issue of Cancers seeks original articles and review manuscripts focused on (1) analyzing tumor EV cargo; (2) EV function in the tumor–microenvironment interplay; (3) their role as modulators of pre-metastatic and metastatic niches across various cancer types; (4) the influence of EVs on immune surveillance against tumors; and finally, (5) EV-based biomarkers and therapeutic development in cancer research.

Dr. Susana García-Silva
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • extracellular vesicles
  • cancer progression
  • tumor microenvironment
  • tumor–immune landscape cross-talk pre-metastatic and metastatic niches
  • immune surveillance
  • EV-based biomarkers
  • EV-based therapeutic development

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3072 KiB  
Article
NK3.3-Derived Extracellular Vesicles Penetrate and Selectively Kill Treatment-Resistant Tumor Cells
by Allyson McCune and Jacki Kornbluth
Cancers 2024, 16(1), 90; https://doi.org/10.3390/cancers16010090 - 23 Dec 2023
Viewed by 952
Abstract
Cancer treatments often become ineffective due to the development of tumor resistance, leading to metastasis and relapse. Treatments may also fail because of their inability to access cells deep within the tumor tissue. When this occurs, new therapeutic agents are needed. We previously [...] Read more.
Cancer treatments often become ineffective due to the development of tumor resistance, leading to metastasis and relapse. Treatments may also fail because of their inability to access cells deep within the tumor tissue. When this occurs, new therapeutic agents are needed. We previously reported that NK3.3EVs, extracellular vesicles (EVs) derived from the normal human natural killer (NK) cell line, NK3.3, have strong cytotoxic activity against leukemia and breast cancer cell lines, without harming normal cells. Here, we used a three-dimensional (3D) MCF7 breast cancer mammosphere model to reproduce a more physiological environment that NK3.3EVs would encounter in vivo. NK3.3EVs penetrated MCF7 mammospheres, inducing death by apoptosis. We generated an imatinib-resistant K562 chronic myeloid leukemia (CML) cell line to investigate whether NK3.3EVs were able to kill tumor cells resistant to front-line chemotherapy. NK3.3EVs were even more cytotoxic to imatinib-resistant cells than parental cells, inducing apoptosis via caspase-3/-7 activation. The small population of cancer stem cells (CSCs) within tumors also contributes to therapeutic resistance. NK3.3EVs reduced the CSC-like CD34+/CD38− subpopulation in imatinib-resistant and parental K562 cultures and decreased CSC-associated expression of tumor-promoting genes. Our results provide strong evidence that NK3.3EVs may be a potential new immunotherapeutic agent for difficult-to-treat cancers. Full article
(This article belongs to the Special Issue Role of Extracellular Vesicles in Cancer Progression)
Show Figures

Graphical abstract

Back to TopTop